Cian O'MAhony

Cian O'MAhony

Auto-generated profile, based on publicly available information

Cian O'MAhony

Pharmaceutical Care Research Group, School of Pharmacy, University College Cork, Cork, Ireland

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 May 2024 in International Journal of Clinical Pharmacy
Verified
Journal Article
Open access
PDF file
COCian O’MAhony
Cian O’MAhony
KDKieran Dalton
Kieran Dalton
LOLeon O’HAgan
Leon O’HAgan
KMKevin D. Murphy
Kevin D. Murphy
CKClare Kinahan
Clare Kinahan
CKCiara Kirke
Ciara Kirke
Background: Medicines reviews by general practice pharmacists improve patient outcomes, but little is known about the associated economic outcomes, particularly in patients at higher risk of medicines-related harm. Aim: To conduct an economic cost-benefit analysis of pharmacists providing person-centred medicines reviews to patients with hyperpolypharmacy (prescribed ≥ 10 regular medicines) and/or at high risk of medicines-related harm across multiple general practice settings. Method: Service delivery costs were calculated based on the pharmacist’s salary, recorded timings, and a general practitioner fee. Direct cost savings were calculated from the cost change of patients’ medicines post review, projected over 1 year. Indirect savings were calculated using two models, a population-based model for avoidance of hospital admissions due to adverse drug reactions and an intervention-based model applying a probability of adverse drug reaction avoidance. Sensitivity analyses were performed using varying workday scenarios. Results: Based on 1471 patients (88.3% with hyperpolypharmacy), the cost of service delivery was €153 per review. Using the population-based model, net cost savings ranging from €198 to €288 per patient review and from €73,317 to €177,696 per annum per pharmacist were calculated. Using the intervention-based model, net cost savings of €651–€741 per review, with corresponding annual savings of €240,870–€457,197 per annum per pharmacist, were calculated. Savings ratios ranged from 181 to 584% across all models and inputs. Conclusion: Person-centred medicines reviews by general practice pharmacists for patients at high risk of medicines-related harm result in substantial cost savings. Wider investment in general practice pharmacists will be beneficial to minimise both patient harm and healthcare system expenditure.

11 April 2022 in PLOS ONE
Verified
Journal Article
Open access
PDF file
PSPaola Salari
Paola Salari
COCian O’mAhony
Cian O’mAhony
SHSéverine Henrard
Séverine Henrard
PWPaco Welsing
Paco Welsing
ABArjun Bhadhuri
Arjun Bhadhuri
MSMatthias Schwenkglenks
Matthias Schwenkglenks
Background: Inappropriate polypharmacy has been linked with adverse outcomes in older, multimorbid adults. OPERAM is a European cluster-randomized trial aimed at testing the effect of a structured pharmacotherapy optimization intervention on preventable drug-related hospital admissions in multimorbid adults with polypharmacy aged 70 years or older. Clinical results of the trial showed a pattern of reduced drug-related hospital admissions, but without statistical significance. In this study we assessed the cost-effectiveness of the pharmacotherapy optimisation intervention.Methods: We performed a pre-planned within-trial cost-effectiveness analysis (CEA) of the OPERAM intervention, from a healthcare system perspective. All data were collected within the trial apart from unit costs. QALYs were computed by applying the crosswalk German valuation algorithm to EQ-5D-5L-based quality of life data. Considering the clustered structure of the data and between-country heterogeneity, we applied Generalized Structural Equation Models (GSEMs) on a multiple imputed sample to estimate costs and QALYs. We also performed analyses by country and subgroup analyses by patient and morbidity characteristics.Results: Trial-wide, the intervention was numerically dominant, with a potential cost-saving of CHF 3’588 (95% confidence interval (CI): -7’716; 540) and gain of 0.025 QALYs (CI: -0.002; 0.052) per patient. Robustness analyses confirmed the validity of the GSEM model. Subgroup analyses suggested stronger effects in people at higher risk.Conclusion: We observed a pattern towards dominance, potentially resulting from an accumulation of multiple small positive intervention effects. Our methodological approaches may inform other CEAs of multi-country, cluster-randomized trials facing presence of missing values and heterogeneity between centres/countries.

10 February 2025 in British Journal of Clinical Pharmacology
Verified
Journal Article
Open access
CKClare Kinahan
Clare Kinahan
CKCiara Kirke
Ciara Kirke
LOLeon O'HAgan
Leon O'HAgan
FMFrank Moriarty
Frank Moriarty
KMKevin D. Murphy
Kevin D. Murphy
KDKieran Dalton
Kieran Dalton
Aim: The aim of this study was to investigate the impact of pharmacist‐led person‐centred medicines reviews in general practices on medicines appropriateness, polypharmacy indicators (high‐risk prescribing markers), and patient‐reported outcome measures (PROMs). Methods: Four pharmacists conducted person‐centred medicines reviews in ten general practices between January 2021 and December 2022 for patients with hyperpolypharmacy (prescribed ≥10 regular medicines) and/or at high risk of medicines‐related harm. Prescribing recommendations were provided to the general practitioner and followed up with patients and/or healthcare professionals. In this single arm study, pre and post intervention: (1) polypharmacy indicators were documented, and for a sample of patients, the (2) Person‐Centred Medication Appropriateness Index (PC‐MAI) scores and (3) PROMs were gathered. Results: Of the 1471 included patients, the mean age was 76 years, 88.4% had hyperpolypharmacy, whilst the mean number of medicines was 13.8 pre and 12.3 post review. Of the 1056 polypharmacy indicator occurrences identified, 70.7% were resolved post review. Of the 194 patients with pre‐review and post‐review PC‐MAI scores, 99% had a reduction; the mean reduction was 17.3 (95% confidence interval [CI] 15.8–18.8, P < .0001) per patient and 1.2 (95% CI 1.0–1.3, P < .0001) per medicine. PROMs were collected for 179 patients; 87.7% reported the review helped their medicines understanding, 63.1% their experience of side effects, 36.9% their ability to take medicines correctly, and 30.5% the impact of medicines on their daily activities. Conclusions: General practice pharmacist‐led person‐centred medicines reviews for patients with hyperpolypharmacy and/or at high risk of medicines‐related harm delivered substantial improvements in medicines appropriateness and patient‐reported outcomes, thus providing evidence to support their wider implementation.

1 October 2021 in European Journal of Oncology Nursing
Verified
Journal Article
Open access
COCian O'MAhony
Cian O'MAhony
KMKevin D. Murphy
Kevin D. Murphy
SBStephen Byrne
Stephen Byrne
Oral anti-cancer therapies offer advantages over parenteral therapies in terms of their non-invasive nature and reduced intrusiveness. However, the shift from directly observed administration of these therapies to home administration means that continuous monitoring is needed. The oral anti-cancer therapy market is rapidly growing, with an ever-increasing number of new medicines available for the patients presenting with cancer illnesses. This study aims to (i) evaluate both the cost of providing monitoring consultations of oral anti-cancer therapies, and (ii) to assess the experience of cancer therapy nurses responsible for the monitoring and their opinions of the quality of the service. This study provides a mixed methods evaluation of the monitoring of oral anti-cancer therapies. Nurses were asked to record the time taken for them to perform their monitoring duties, and staff related costs were calculated using publicly available salary data. Patient-related costs were calculated using the Human Capital method. Nurses were asked to discuss their experience of monitoring oral anti-cancer therapies in semi-structured interviews. These interviews were subsequently analysed using thematic analysis. 201 recordings and their associated costs were documented. The median consultation time was 33 min, costing €22.10 using Clinical Nurse Specialist salary figures and €26.51 using Advanced Nurse Practitioner salary figures. The associated patient cost was €14.06. Themes of the effect of Covid-19 on the service, expanding and complicated care package requirements, the need for dedicated oral clinics and the future of the service emerged from the interview data. The monitoring service provided by nurses may be undervalued. The commitment to fully dedicated oral anti-cancer therapy clinics and an increase in staff to align with the ongoing increase in service demand is seen as vital for the continued safe and effective delivery of this specialist cancer service.

5 May 2026 in International Journal of Clinical Pharmacy
Verified
Journal Article
Open access
PDF file
COCian O’MAhony
Cian O’MAhony
KDKieran Dalton
Kieran Dalton
LOLeon O’HAgan
Leon O’HAgan
KMKevin D. Murphy
Kevin D. Murphy
CKClare Kinahan
Clare Kinahan
CKCiara Kirke
Ciara Kirke